Pharma

Your Article Summary

See Latest Articles

Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
Corporate News Releases - The Healthcare Sales & Marketing Network, 11/26/08

Johnson & Johnson and Omrix Biopharmaceuticals, Inc., a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer. Omrix is expected to operate as a stand-alone entity reporting through ETHICON, Inc., a Johnson & Johnson company and leading provider of suture, mesh, hemostats and other products for a wide range of surgical procedures.

Today in M&A/Partnerships...keeping you current

Receive free subspecialty "5-minute updates" via email

Covidien Announces Definitive Agreement to Sell U.S. Radiopharmacies
Covidien, 12/18/09

MediciNova and Avigen Stockholders Approve Merger
Avigen, 12/18/09

GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09

 See all of M&A/Partnerships